Home » Australia Approves Smartphone Diagnostic for Acute Pediatric Respiratory Disease
Australia Approves Smartphone Diagnostic for Acute Pediatric Respiratory Disease
Australia’s Therapeutic Goods Administration (TGA) has approved ResApp’s ResAppDx-EU, a smartphone-based app for diagnosing and managing respiratory disease in pediatric patients.
The app previously received the CE Mark, which was supported by data from a pediatric clinical study showing that the app’s cough-based diagnosis algorithms had “excellent agreement with a clinical diagnosis,” the company said.
The mobile software app is intended for use by clinicians to diagnose lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease and bronchiolitis in infants and children.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May